Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design

被引：30

作者：

Venkatraman, S ^{[1
]}

Njoroge, FG ^{[1
]}

Girijavallabhan, VM ^{[1
]}

Madison, VS ^{[1
]}

Yao, NH ^{[1
]}

Prongay, AJ ^{[1
]}

Butkiewicz, N ^{[1
]}

Pichardo, J ^{[1
]}

机构：

[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA

来源：

JOURNAL OF MEDICINAL CHEMISTRY | 2005年 / 48卷 / 16期

关键词：

D O I：

10.1021/jm0489556

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Hepatitus C virus (HCV) NS3, when bound to NS-4A cofactor, facilitates development of mature virons by catalyzing cleavage of a polyprotein to form functional and structural proteins of HCV. The enzyme has a shallow binding pocket at the catalytic site, making development of inhibitors difficult. We have designed, preorganized, and depeptidized macrocyclic inhibitors from P-4 to P-2' and optimized binding to 0.1 mu M. The structure of an inhibitor bound to the enzyme was also solved.

引用

页码：5088 / 5091

页数：4

共 50 条

[21] Structure-based design of macrocyclic kinase inhibitors
Poulsen, Anders
Wiliam, Anthony D.
Blanchard, Steephanie
Dymock, Brian
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 246
[22] Determinants for Substrate Selectivity of the Hepatitis C Virus NS3-4A Protease
Tran, Huong T. L.
Gouttenoire, Jerome
Moradpour, Darius
SWISS MEDICAL WEEKLY, 2013, 143 : 8S - 8S
[23] Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors
Letitia Shunmugam
Pritika Ramharack
Mahmoud E. S. Soliman
The Protein Journal, 2017, 36 : 397 - 406
[24] Road Map for the Structure-Based Design of Selective Covalent HCV NS3/4A Protease Inhibitors
Shunmugam, Letitia
Ramharack, Pritika
Soliman, Mahmoud E. S.
PROTEIN JOURNAL, 2017, 36 (05) : 397 - 406
[25] Hepatitis C Viral NS3-4A Protease Activity Is Enhanced by the NS3 Helicase
Beran, Rudolf K. F.
Pyle, Anna Marie
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (44) : 29929 - 29937
[26] Structure-based design of parasitic protease inhibitors
Li, RS
Chen, XW
Gong, BQ
Selzer, PM
Li, Z
Davidson, E
Kurzban, G
Miller, RE
Nuzum, EO
McKerrow, JH
Fletterick, RJ
Gillmor, SA
Craik, CS
Kuntz, ID
Cohen, FE
Kenyon, GL
BIOORGANIC & MEDICINAL CHEMISTRY, 1996, 4 (09) : 1421 - 1427
[27] STRUCTURE-BASED DESIGN OF ASPARTYL PROTEASE INHIBITORS
THAISRIVONGS, S
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1995, 209 : 20 - CINF
[28] Discovery of novel allosteric inhibitors of HCV NS3/4a enzyme via structure-based drug design Discovery of novel allosteric inhibitors of HCV NS3/4a enzyme via structure-based drug design
Pathuri, Puja
Saalau-Bethell, Susanne M.
Woodhead, Andrew J.
Carr, Maria G.
Chessari, Gianni
Coyle, Joseph
Frederickson, Martyn
Graham, Brent
Hamlett, Chris
Hiscock, Steven D.
Holding, Finn P.
Jhoti, Harren
McMenamin, Rachel
Murray, Chris W.
Reader, Mike
Rees, David C.
Rich, Sharna J.
Richardson, Caroline J.
Thompson, Neil
Verdonk, Marcel L.
Vinkovic, Mladen
Williams, Pamela A.
Yon, Jeff
ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2012, 68 : S27 - S27
[29] Searching for Novel Cellular Targets of the Hepatitis C Virus NS3-4A Protease
Morikawa, Kenichi
Gouttenoire, Jerome
Bellecave, Pantxika
Lange, Christian M.
Kennel, Audrey
Quadroni, Manfredo
Moradpour, Darius
SWISS MEDICAL WEEKLY, 2011, 141 : 19S - 19S
[30] Synthesis of cyclopropyl peptidomimetics as potential BACE and HCV NS3-4a protease inhibitors
Dunlap, Norma
Gouger, Daniel H.
Carter, Christine
Alemayehu, Biruk
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243

← 1 2 3 4 5 →